Develop tools such as vaccine platforms and expression systems immunological toolboxes and delivery systems

SOA

Internal project

Develop tools such as vaccine platforms and expression systems, immunological toolboxes and delivery systems

Action 2 - Leading Institute: DTU

Project summary

Prevention is better than cure, and vaccine-based disease prophylaxis represents a key element in sustainable animal farming with high animal health and welfare. For a range of infectious diseases in farmed animals, vaccines are either not available or insufficient. This project aims at developing/improving/consolidating a range of new vaccine technologies along with tools to evaluate/predict protective efficacy of vaccines for use in animal husbandry including aquaculture.

Project objectives

Identify and improve vaccine antigens

Implement vaccine platforms such as:
Nano and microparticle based vaccines
Nucleic acid vaccines
Extracellular vesicle and yeast-based vaccines
Viral vector and reverse genetic vaccines
Mycoplasma based vaccines

Develop, improve and evaluate delivery strategies, adjuvants and formulations for vaccines

Develop tools to evaluate the host response to vaccine and vaccine adjuvants including:

Tools to characterize protective immune response
In vitro immune assays for monitoring host immune response to vaccination
Profiling bioinformatics to identify immune signatures of potent vaccines
Assays correlating with vaccine-induced immunity and vaccine efficacy.
Develop tools for studying interaction between bacterial vector vaccines and gut microbiota.

Outcomes and impacts

New and improved veterinary vaccines and vaccine adjuvants
New tools for evaluation and monitoring vaccine induced immune responses and correlates of protection
Tools for future improved disease prophylaxis in farmed animal, which will contribute to improved animal welfare, sustainable animal production and green transition.

Priority Area 4

Treatments & vaccines

Operational objective (OO8)

To develop new vaccines or improve existing vaccines, including adjuvants and immune-modulators

Key words

Vaccine antigens and platforms

vaccine delivery and formulation

vaccine response monitoring tools

adjuvants

Publications

Rapid Quantification of Bluetongue Virus-Neutralizing Antibodies Using Bioluminescent Reporter-Expressing Viruses

Heterologous DNA–Adenovirus Prime–Boost Strategy Expressing Bluetongue Virus VP2 and VP7 Proteins Protects Against Virulent Challenge

Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(−/−) mice